biolog
respons
modifi
brm
recent
term
first
coin
connot
agent
treatment
approach
whose
perceiv
action
involv
modif
individu
bio
logic
respons
prior
term
immunotherapi
use
refer
agent
usual
refer
naturallyoccur
product
obtain
test
variou
grade
puriti
perhap
oldest
strategi
immun
modif
good
host
bacteri
vaccin
first
develop
microb
centuri
antimicrobi
vaccin
wellestablish
part
standard
medic
practic
anticanc
vaccin
remain
development
stage
latter
vaccin
extract
speci
use
origin
vaccin
coley
undergo
clinic
test
howev
advent
hybridoma
recombin
dna
gene
insert
technolog
explos
widen
number
agent
avail
clinic
test
agent
call
brm
rang
monoclon
antibodi
recombin
form
interferon
interleukin
colonystimul
factor
csf
tradit
chines
medicin
review
focu
primarili
agent
whose
mechan
action
least
partial
understood
may
soon
appli
infecti
diseas
agent
product
creativ
technolog
mention
natur
product
whose
properti
may
uniqu
complementari
technologicallyproduc
product
discuss
summari
agent
present
tabl
rational
product
clinic
applic
brm
infecti
diseas
come
grow
understand
inflammatori
respons
infecti
agent
two
recent
articl
review
respons
detail
perspect
degre
infect
interact
hypothalamicpituitaryadren
hpa
axi
immun
system
evid
infecti
agent
act
stressor
advers
alter
hpa
axi
respons
agent
thu
disrupt
normal
inflammatori
respons
glucocorticosteroid
play
vital
role
intens
immun
respons
sever
level
includ
gene
express
transcript
translat
posttransl
process
secret
protein
cell
progenitor
prolifer
differenti
effect
inhibitori
virtual
level
immun
system
includ
macrophag
antigen
present
bcell
product
antibodi
prolifer
differenti
lymphocyt
granulocyt
effector
cell
inhibitori
effect
turn
mediat
inhibit
ofinterleukin
il
well
suppressor
oftumour
necrosi
factor
tnf
gamma
interferon
endogen
csf
granulocytemacrophag
csf
gmcsf
inhibit
prevent
neutropenia
congenit
cyclic
neutropen
state
prevent
neutropenia
intens
anticanc
therapi
treatment
febril
neutropenia
prevent
treatment
aidsrel
neutropenia
infect
treatment
antibiot
infect
variou
immunocompromis
state
eg
burn
asplenia
neonat
infect
improv
hematopoiesi
tcell
bcell
helper
factor
stimul
thrombopoiesi
downregul
interact
growth
factor
amplifi
hematopoiesi
block
shocklik
effect
ivig
kawasaki
diseas
prevent
treatment
viral
diseas
immunocompromis
patient
treatment
neonat
bacteri
infect
treatment
prevent
infect
burn
patient
antiendotoxin
antibodi
prevent
sepsi
antiidiotyp
antibodi
vaccin
nucleic
acid
analog
isoprinosin
thiol
diethyldithiocarbon
cyanoaziridin
azimexon
herbal
prepar
proinflammatori
mediat
prostaglandin
leukotrin
glucocorticosteroid
also
suppress
inhibit
function
ofeffector
cell
eosinophil
mast
cell
neutrophil
monocytemacrophag
thu
product
inhibit
inflamm
complex
phenomenon
involv
varieti
mediat
whose
human
gene
identifi
produc
clinic
intervent
patient
local
infect
complet
resolut
without
aid
antibiot
rule
otherwis
healthi
host
individu
may
requir
exogenouslyadminist
therapi
much
learn
respons
endogen
mediat
could
use
immunodefici
host
exampl
studi
shown
alveolar
macrophag
produc
gcsf
respons
infecti
agent
vitro
gcsf
shown
improv
function
activ
surviv
granulocyt
pathogen
candida
sp
staph
aureu
p
aeruginosa
variou
factor
may
contribut
host
failur
local
contain
infect
includ
disrupt
local
barrier
infect
dissemin
burn
trauma
advanc
age
presenc
underli
disord
renal
cardiac
failur
diabet
mellitu
hepat
cirrhosi
asplenia
concomit
administr
immunosuppress
drug
way
yet
fulli
understood
factor
alter
complex
equilibrium
mediat
enhanc
inflamm
suppress
factor
mention
may
detriment
upset
balanc
sever
way
alter
capabl
target
cell
releas
mediat
disturb
type
qualiti
interdepend
mediat
local
environ
inflamm
normal
control
countereffect
mediat
enhanc
suppress
inflamm
tnfo
enhanc
prostaglandin
releas
latter
downregul
tnf
product
similarli
gcsf
tnf
improv
neutrophil
function
product
neutrophil
burst
neutral
effect
leukotrin
increas
vascular
permeabl
inflammatori
site
howev
mediat
interact
selfperpetu
lead
infect
dissemin
sepsi
exampl
includ
releas
activ
tcell
stimul
macrophag
releas
latter
induc
releas
tnf
plateletactiv
factor
paf
three
factor
promot
releas
sinc
three
factor
induc
symptom
sepsi
much
research
direct
toward
understand
relationship
state
sepsi
develop
counterintervent
may
prevent
revers
septic
state
import
vascular
endothelium
evolut
septic
state
rapidli
becom
evid
defens
system
mechan
barrier
infect
mediat
releas
local
environ
also
sourc
tnf
ill
paf
endotheliumderiv
relax
factor
edrf
arachidon
acid
metabolit
limit
releas
tnf
endotoxin
etc
induc
downregul
subsequ
mediat
releas
result
abort
process
sepsi
develop
downregul
could
prevent
shortag
downregul
mediat
overwhelm
releas
sepsisinduc
mediat
substanc
may
damag
endothelium
result
releas
sepsispromot
factor
eventu
develop
endorgan
ischemia
multipl
organ
failur
final
stage
sepsi
multipl
organ
failur
mof
wellrecogn
clinic
syndrom
associ
wide
varieti
clinic
event
state
infect
shock
lead
list
predispos
factor
other
includ
mechan
thermal
traumat
factor
pancreat
sever
mechan
mof
evolut
put
forward
socal
macrophag
hypothesi
support
previouslyoutlin
evolut
sepsi
via
endogen
moder
uncheck
releas
oqf
tnfo
selfperpetu
interact
agent
form
basi
hypothesi
summari
sever
endogen
produc
cytokin
implic
import
promot
process
sepsi
remaind
review
strategi
focu
suppress
uncontrol
releas
sepsispromot
agent
stimul
exogen
restor
sepsisprev
agent
present
end
agent
strategi
show
promis
whose
mechan
action
less
clear
also
review
gcsf
gmcsf
first
csf
approv
clinic
use
cancer
patient
effect
either
agent
demonstr
clinic
situat
infect
prevent
primari
concern
congenit
idiopath
chronic
cyclic
neutropenia
follow
standard
dose
myelosuppress
chemotherapi
coniunct
bone
marrow
transplant
bmt
peripher
blood
stem
cell
pbsc
reconstitut
support
follow
myeloabl
therapi
support
therapi
patient
aid
gcsf
reduc
infect
hospit
febril
neutropenia
rate
well
frequenc
durat
antibiot
usag
random
trial
patient
treat
myelosuppress
therapi
small
cell
lung
cancer
side
effect
minim
surviv
similar
whether
gcsf
given
gmcsf
test
set
random
trial
situat
fever
flulik
symptom
frequent
gcsf
complet
random
trial
publish
compar
prophylact
antibiot
gcsf
gmcsf
trial
conduct
compar
effect
gcsf
antibiot
compar
antibiot
alon
set
febril
neutropenia
follow
standard
dose
chemotherapi
patient
undergo
autolog
bmt
random
trial
demonstr
acceler
neutrophil
recoveri
reduc
durat
antibiot
therapi
hospit
gmcsf
compar
placebo
trial
gcsf
undertaken
nonrandom
studi
suggest
possibl
benefici
effect
pbsc
harvest
effici
gcsf
gmcsf
without
benefit
postchemotherapi
rebound
phase
whether
posttransplant
peripher
blood
cell
recoveri
improv
addit
either
factor
yet
clear
optim
schedul
csf
one
sever
issu
remain
outstand
support
care
patient
chronic
neutropen
diseas
made
major
advanc
due
csf
patient
congenit
idiopath
neutropenia
treat
year
gcsf
associ
elev
neutrophil
count
x
mark
reduct
infectionrel
symptom
advers
event
chronic
treatment
infrequ
gener
mild
except
occasion
thrombocytopenia
bone
pain
hypersplen
treatment
gmcsf
less
effect
also
produc
eosinophilia
patient
cyclic
neutropenia
regular
day
cycl
neutropenia
result
recurr
fever
infect
mucos
ulcer
treatment
gcsf
result
reduc
frequenc
three
clinic
problem
coincid
elev
cyclic
nadir
shorten
cycl
length
chronic
therapi
appear
result
stem
cell
deplet
experi
gmcsf
limit
result
elev
neutrophil
level
patient
aid
may
undergo
primari
bone
marrow
failur
myelosuppress
due
antivir
support
antiinfect
therapi
gcsf
demonstr
mark
improv
neutrophil
count
patient
anemia
neutropenia
also
receiv
erythropoietin
zidovudin
therapi
allow
treatment
zidovudin
zidovudineinduc
myelosuppress
correct
similar
benefit
seen
gmcsf
wherea
hiv
antigen
level
unchang
gcsf
latter
level
elev
gmcsf
suggest
possibl
enhanc
hiv
prolifer
howev
offset
enhanc
antivir
effect
zidovudin
presenc
gmcsf
suggest
vitro
nonneutropen
state
infect
may
spread
due
disrupt
circumvent
normal
barrier
eg
burn
intramuscular
infect
state
immun
defici
acquir
eg
neonat
sepsi
asplen
state
anim
model
studi
suggest
possibl
role
csf
situat
burn
patient
demonstr
multipl
defect
neutrophil
dysfunct
preced
sepsi
murin
model
burn
infect
p
aeruginosa
mice
treat
gcsf
show
mark
improv
surviv
compar
salinetr
control
anoth
studi
model
mice
receiv
singl
dose
gentamicin
plu
gcsf
day
demonstr
improv
surviv
compar
mice
treat
gcsf
alon
p
gentamicin
alon
p
neither
treatment
p
newborn
group
b
streptococcu
common
caus
neonat
sepsi
studi
neonat
rat
group
b
streptococcu
given
subcutan
sc
surviv
anim
h
receiv
gcsf
antibiot
ampicillin
gentamicin
antibiot
alon
gcsf
alon
treatment
p
compar
control
murin
model
ofintraabdomin
sepsi
use
cecal
ligat
punctur
clp
oreilli
et
al
show
dosedepend
increas
surviv
mice
receiv
ng
gcsf
clp
continu
day
compar
control
receiv
gcsf
begin
day
prior
clp
continu
week
postclp
significantli
better
surviv
dose
test
rang
compar
control
given
gentamicin
set
two
intervent
togeth
show
surviv
similar
gentamicin
alon
splenectomi
associ
increas
incid
encapsul
organ
infect
particularli
pneumococcu
mous
model
pulmonari
infect
aerosol
streptococcu
pneumonia
hebert
et
al
report
surviv
splenectom
mice
treat
gcsf
h
prior
day
follow
infect
compar
surviv
salinetr
splenectom
control
p
alcohol
abus
increas
risk
sever
pneumonia
impair
neutrophil
migrat
infect
site
implic
caus
studi
rat
treat
gcsf
vehicl
day
follow
ip
administr
ethanol
salin
prior
intratrach
challeng
klebsiella
pneumonia
rat
receiv
ethanol
without
gcsf
develop
bacteremia
none
receiv
gcsf
prior
ethanol
becam
bacterem
furthermor
twelv
ethanoltr
control
die
h
wherea
pretreat
gcsf
die
studi
pulmonari
infect
due
p
aerugenosa
model
produc
similar
result
studi
suggest
role
csf
parasit
less
common
bacteri
infect
function
improv
eosinophil
seen
gmcsf
may
suggest
role
parasit
infect
schistosoma
mansoni
gmcsf
improv
adher
kill
organ
eosinophil
vitro
cheer
et
al
demonstr
suscept
listeria
monocytogen
infect
endogen
respons
mcsf
gcsf
level
may
part
genet
basi
least
mice
note
gmcsf
may
associ
advers
outcom
compar
gmcsf
patient
sepsi
preliminari
observ
found
gmcsf
treatment
associ
twentyfold
increas
endogen
serum
tnf
level
follow
iv
endotoxin
challeng
rat
effect
tnf
level
found
use
gcsf
human
peripher
blood
monocyt
also
found
produc
tnf
stimul
gmcsf
vitro
data
support
hypothesi
clinic
sepsi
may
initi
exacerb
agent
stimul
tnf
product
vivo
use
agent
patient
must
test
care
even
concomit
treatment
antibiot
use
understand
potenti
clinic
consequ
relat
infecti
diseas
refer
two
genet
chemic
distinct
polypeptid
recogn
receptor
share
biolog
activ
term
interleukin
mislead
context
divers
sourc
includ
macrophag
monocyt
neutrophil
tand
blymphocyt
astrocyt
endotheli
cell
keratinocyt
intestin
epithelium
matern
placent
cell
other
leukem
cell
produc
known
sinc
heatlabil
protein
extract
exud
fluid
known
endogen
pyrogen
sinc
discoveri
widerang
biolog
properti
led
success
synonym
catabolin
osteoclast
activ
factor
lymphocyt
prolifer
promot
factor
ofneutrophil
tumourinhibit
properti
well
structur
genet
aspect
eloqu
review
previous
review
focu
aspect
appli
sepsi
aspect
infecti
diseas
autostimul
gene
express
synthesi
monocyt
endotheli
cell
product
induc
mcsf
gmcsf
tnf
inhibit
thelper
cell
product
inhibit
lipopolysaccharid
lp
induc
product
endotoxin
may
potent
induc
endogen
exotoxin
gramposit
organ
staphylococci
streptococci
also
stimul
well
tnf
product
mechan
implic
develop
toxic
shock
syndrom
given
patient
cancer
phase
trial
produc
fever
arthralgia
myalgia
headach
anorexia
insomnia
gastrointestin
upset
dose
rang
ngkg
effect
pronounc
given
iv
compar
sc
increas
circul
neutrophil
platelet
seen
observ
confirm
biolog
effect
seen
anim
model
hematopoiet
effect
excit
potenti
therapi
eventu
character
illo
differ
activ
found
illa
anim
model
ili
acceler
neutrophil
recoveri
lethallyirradi
mice
low
prophylact
dose
shown
acceler
recoveri
chemotherapyinduc
neutropenia
mice
protect
mice
infect
p
aeruginosa
cyclophosphamideinduc
neutropenia
whether
gentamicin
administ
well
direct
antibacteri
effect
unlik
mechan
effect
unclear
howev
paradox
protect
agent
known
mediat
sepsi
like
critic
depend
dose
given
low
dose
time
administr
endogen
releas
gcsf
gmcsf
endotheli
bone
marrow
stromal
cell
report
may
play
role
addit
act
directli
synergist
respons
earli
progenitor
stem
cell
csf
direct
effect
stem
cell
differenti
prolifer
may
induc
stem
cell
factor
final
regul
cell
cycl
progenitor
may
allow
protect
cell
cytotox
agent
chang
short
exposur
probabl
import
permit
effect
avoid
induct
septic
phenomena
continu
exposur
vivo
lead
tnfmediat
myelosuppress
benefici
effect
low
dose
may
also
mediat
observ
downregul
tnf
receptor
mediat
oxygen
scaveng
molecul
induct
corticosteroid
catabol
effect
includ
induct
anorexia
weight
loss
latter
shown
block
antibodi
receptor
featur
advers
contribut
sepsi
syndrom
profound
seriou
effect
vascular
system
induc
dose
ggkg
iv
hypotens
doselimit
effect
ngkg
cyclooxygenas
inhibitor
block
effect
well
hypotens
induc
combin
tnf
immunolog
activ
tcell
induct
although
clear
whether
requir
tcell
activ
tcell
act
helper
factor
factor
activ
bcell
furthermor
cell
includ
bcell
act
accessori
cell
antigen
recognit
produc
suggest
fundament
role
ill
earli
step
immun
recognit
foreign
antigen
synergist
action
tnf
allud
earlier
like
tnf
induc
shock
potent
regard
howev
rabbit
primat
antibodi
tnf
prevent
endotoxininduc
shock
associ
suppress
serum
level
suggest
tnf
may
control
product
data
suggest
monoclon
antibodi
tnf
andor
use
receptor
antagonist
could
therapeut
use
shocklik
state
tnf
like
induc
csf
releas
vivo
act
synergist
tnf
protect
rat
lethal
irradi
endogen
pyrogen
elev
serum
level
correl
sever
fever
sepsi
patient
howev
may
serv
downregul
thu
counter
effect
perhap
import
interact
involv
hematopoiesi
togeth
agent
stimul
multilineag
coloni
format
murin
bone
marrow
cell
exposur
chemotherapi
vitro
howev
time
exposur
may
determin
whether
effect
myeloprotect
detriment
induc
progenitor
prolifer
close
cytotox
exposur
discoveri
agent
antagonist
shocklik
effect
tnf
endotoxin
may
afford
us
therapeut
tool
prevent
treat
sepsi
directli
interf
endogen
mediat
sepsi
illra
inhibitor
one
sever
naturallyoccur
inhibitor
other
includ
lipid
lipoprotein
tgf
neuropeptid
macroglobulin
form
tammhorsfal
protein
latter
substanc
also
inhibit
cytokin
other
detect
specif
inhibit
sourc
inhibitor
includ
endotoxintr
volunt
urinari
extract
febril
patient
patient
leukemia
substanc
known
illra
small
naturallyoccur
protein
block
bind
tcell
fibroblast
bind
recombin
human
illra
ra
develop
biolog
properti
ident
natur
form
rabbit
baboon
rhuillra
prevent
septic
shock
syndrom
induc
e
coli
suspens
rabbit
inflammatori
bowel
diseas
model
induc
ra
prevent
immun
complexmedi
diseas
potenti
clinic
role
rhuillra
includ
inhibit
ectop
secret
variou
malign
reduct
inflamm
phase
clinic
test
underway
human
strategi
evolv
prevent
treatment
sepsi
human
polyclon
antiserum
produc
endotoxin
core
determin
shown
reduc
mortal
clinic
trial
patient
experienc
gramneg
bacteremia
reduc
incid
septic
shock
surgic
patient
high
risk
suggest
mechan
protect
may
occur
includ
inhibit
neutrophil
prime
endotoxin
enhanc
endotoxin
bind
clearanc
inhibit
tnf
product
antiserum
produc
inject
volunt
mutant
e
coli
known
induc
strain
yield
rel
specif
immun
respons
lipid
core
compon
anoth
human
polyclon
igm
produc
salmonella
sp
strain
protect
anim
lethal
challeng
sever
gramneg
bacteri
strain
howev
commerci
product
hinder
toxic
donor
theoret
risk
infect
transmiss
pool
human
serum
variabl
antibodi
titr
booster
respons
could
allow
multipl
donat
howev
monoclon
antibodi
moab
technolog
permit
develop
highli
specif
antibodi
lipid
domain
ofendotoxin
use
e
coli
vaccin
mention
human
monoclon
igm
known
found
clonal
select
bind
endotoxin
among
broad
rang
clinic
isol
gramneg
bacteria
bind
appear
enhanc
concomit
presenc
ceftazidin
rabbit
protect
septic
death
due
pseudomona
bacteremia
crossreact
polyclon
igm
prepar
mutant
howev
anim
studi
anticor
antiserum
shown
protect
interspeci
differ
rel
low
affin
anticor
antiserum
variat
method
produc
purifi
moab
cite
possibl
reason
recent
blind
placebocontrol
random
trial
standard
canin
model
endotox
shock
show
antiendotox
effect
decreas
surviv
treat
group
random
clinic
trial
human
igg
e
coli
demonstr
protect
gramneg
shock
igm
may
necessari
protect
test
human
phase
phase
ii
trial
safeti
protect
sepsi
demonstr
random
doubleblind
placebocontrol
trial
treat
patient
sepsi
cultureproven
gramneg
bacteremia
caus
moab
placebo
human
serum
albumin
administ
singl
iv
inject
min
immedi
follow
enrol
intervent
antibiot
corticosteroid
cardiac
respiratori
support
control
patient
elig
develop
sepsi
accord
standard
definit
followup
day
patient
cultureproven
gramneg
bacteremia
statist
signific
reduct
death
seen
among
treat
patient
versu
placebo
p
benefit
found
among
patient
sepsi
without
cultureproven
gramneg
bacteremia
p
similarli
mortal
reduct
seen
patient
analyz
p
followup
period
report
short
result
provoc
conclus
treat
patient
sepsi
suspect
necessarili
proven
due
gramneg
bacteremia
howev
valid
studi
question
ground
methodolog
flaw
furthermor
critic
subsequ
public
canin
model
studi
cite
lower
justif
use
clinic
practic
inform
subgroup
patient
may
benefit
avail
critic
concern
express
wolff
suggest
nonspecif
igm
could
better
control
test
specif
natur
protect
polyclon
antiserum
could
control
howev
sinc
neither
use
standard
treatment
decis
use
albumin
appropri
subsequ
publish
respons
random
trial
suggest
patient
without
proven
gramneg
bacteremia
receiv
may
higher
mortal
rate
subsequ
cost
analysi
studi
assess
cost
treat
patient
sepsi
studi
versu
treat
cultureproven
case
assum
avail
rapid
test
gramneg
sepsi
present
avail
former
strategi
prevent
averag
death
per
treat
patient
costeffect
per
year
life
save
latter
strategi
yield
costeffect
per
year
life
save
sensit
analysi
demonstr
import
patient
select
exampl
patient
proven
gramneg
bacteremia
patient
treat
costeffect
would
deterior
per
year
life
save
anoth
monoclon
antibodi
endotoxin
known
test
multicent
doubleblind
random
clinic
trial
fourhundredandeightysix
hospit
patient
sign
gramneg
infect
sepsi
enrol
entri
patient
receiv
singl
dose
placebo
follow
treatment
h
later
threehundredandsixteen
patient
gramneg
sepsi
confirm
bacteremia
document
surviv
differ
among
treatment
group
overal
subgroup
analysi
found
signific
surviv
advantag
patient
gramneg
sepsi
shock
receiv
compar
receiv
placebo
p
resolut
organ
failur
frequent
group
versu
p
toxic
infrequ
revers
recent
studi
also
suggest
may
improv
surviv
ciprofloxacintr
anim
neutropen
rat
model
pseudomona
sepsi
random
placebocontrol
trial
compar
clear
signific
reduct
mortal
found
among
patient
treat
moab
trial
differ
subset
patient
seem
benefit
two
trial
patient
constitut
minor
studi
patient
recent
statement
guidelin
infecti
diseas
societi
america
wenzel
et
al
conclud
conclus
evid
reduct
mortal
rate
use
ofendotoxin
antibodi
avail
clearli
need
research
factor
prospect
identifi
patient
sepsi
would
benefit
excit
somewhat
costli
new
intervent
despit
avail
use
immunoglobulin
patient
sinc
recent
consensu
develop
confer
report
recommend
ivig
without
reserv
two
nonimmunodefici
condit
acut
autoimmun
thrombocytopen
purpura
childhood
kawasaki
syndrom
due
part
long
time
requir
develop
concentr
safe
prepar
iv
use
also
due
rel
low
level
evid
literatur
ivig
clinic
effect
nine
commerci
prepar
avail
variabl
physic
featur
specif
antibodi
titr
exist
amongst
prepar
well
lot
lot
prepar
mechan
ivig
may
effect
still
specul
attent
focus
role
antiidiotyp
antibodi
aia
prepar
detail
review
role
antibodi
normal
antibodi
feedback
regul
avail
essenc
ivig
may
induc
reticuloendotheli
blockad
increas
tsuppressor
natur
killer
cell
andor
may
decreas
antibodi
synthesi
aia
within
ivig
may
neutral
autoantibodi
may
block
bcell
receptor
antigen
thu
block
autoantibodi
product
may
complex
idiotyp
complement
activ
differ
tcell
subset
anim
model
aia
ivig
shown
decreas
autoantibodi
product
situat
involv
infecti
diseas
ivig
may
use
includ
prevent
treatment
cytomegaloviru
cmv
prevent
varicella
zoster
vz
infect
kawasaki
syndrom
neonat
risk
group
b
streptococc
infect
possibl
children
hiv
infect
patient
primari
hypogammaglobulinemia
also
may
benefit
mention
two
studi
demonstr
efficaci
ivig
kawasaki
syndrom
two
control
trial
show
fewer
coronari
arteri
abnorm
highdos
ivig
aspirin
compar
aspirin
alon
evid
suggest
ivig
may
alter
effect
cytokin
excess
produc
bacteri
toxin
block
effect
toxin
altern
suppress
activ
tcell
may
play
role
next
convinc
clinic
situat
ivig
efficaci
involv
infecti
diseas
prevent
cmv
infect
immunodefici
particularli
transplant
patient
clinic
trial
support
reduct
incid
cmv
interstiti
pneumonia
infect
per
se
one
nonrandom
trial
suggest
cmv
infect
could
reduc
ivig
effect
appear
depend
evid
previou
cmv
infect
recipi
donor
studi
seroneg
recipi
donor
show
benefit
ivig
achiev
seroneg
donor
blood
product
benefit
also
suggest
patient
cmv
infect
receiv
ivig
ganciclovir
patient
receiv
either
intervent
surviv
rate
receiv
chanc
surviv
recent
random
trial
design
test
abil
ivig
reduc
morbid
allogen
transplant
primari
secondari
outcom
includ
graft
versu
host
diseas
gvhd
well
infect
rate
threehundredandeightytwo
patient
receiv
ivig
ivig
weekli
day
posttranspl
monthli
day
cmvseroposit
patient
receiv
prophylact
acyclovir
patient
receiv
cotrimoxasol
ganciclovir
ad
cmv
pneumonia
develop
surviv
two
group
ident
ivig
howev
associ
reduc
risk
gvhd
gramneg
septicemia
local
infect
reduc
risk
interstiti
pneumon
among
cmvseroposit
patient
data
also
show
reduct
mortal
due
tumour
relaps
ivigtr
group
age
studi
requir
determin
longterm
effect
ivig
set
renal
transplant
patient
also
benefit
ivig
may
costeffect
seroneg
recipi
threefold
reduct
incid
cmv
infect
patient
hypogammaglobulinemia
may
experi
fewer
cmv
infect
given
ivig
cmv
infect
common
problem
patient
acquir
immunodefici
syndrom
aid
potenti
enthusiasm
prophylact
ivig
popul
may
temper
fact
cmv
often
result
endogen
reactiv
set
may
reduc
effect
intervent
may
said
pneumocysti
carinii
infect
two
nonrandom
studi
suggest
improv
surviv
associ
ivig
therapi
period
children
aid
receiv
ivig
antibiot
need
die
compar
patient
treat
antibiot
alon
siegel
olesk
report
death
untreat
children
aid
year
compar
patient
receiv
ivig
coincid
improv
immunoregulatori
function
also
report
howev
control
trial
nation
institut
child
health
human
develop
found
improv
mortal
use
ivig
compar
placebo
infect
risk
reduc
patient
count
per
litr
unfortun
zidovudin
standard
treatment
therefor
relev
result
question
random
trial
compar
ivig
appropri
antibiot
would
help
area
ivig
use
prevent
treatment
viral
ill
ivig
may
effect
vz
immun
globulin
immunocompromis
children
unabl
take
latter
vz
infect
prevent
vz
antibodi
titer
similar
appropri
dose
ivig
howev
evid
ivig
improv
recoveri
patient
establish
vz
infect
ivig
shorten
hospit
time
death
occur
either
arm
doubleblind
random
placebocontrol
trial
children
respiratori
syncyti
viru
pneumon
random
trial
avail
treatment
adenoviru
influenza
parainfluenza
virus
uncontrol
studi
suggest
ivig
may
improv
symptom
andor
recoveri
patient
hypogammoglobulinemia
echovirusassoci
polymyos
meningoenceph
well
patient
chronic
epsteinbarr
viru
ebv
infect
anoth
diseas
may
relat
ebv
infect
author
doubleblind
placebocontrol
trial
adult
chronic
fatigu
syndrom
report
improv
symptom
elev
level
work
leisur
social
activ
inform
obtain
interview
followup
even
smaller
random
trial
report
clinic
benefit
studi
suffer
high
type
ii
error
studi
design
ivig
suggest
ebvseroneg
boy
xlink
lymphoprolif
syndrom
frequent
fatal
outcom
diseas
mention
earlier
ivig
use
manag
bacteriallymedi
neonat
sepsi
two
uncontrol
studi
reportedli
demonstr
improv
surviv
patient
suspect
neonat
sepsi
treat
ivig
plu
antibiot
versu
antibiot
alon
benefit
particularli
evid
among
lowbirth
weight
prematur
infant
despit
result
minim
advers
side
effect
level
evid
consid
insuffici
support
use
standard
therapi
nih
consensu
confer
random
compar
trial
need
patient
burn
could
also
theoret
benefit
ivig
prevent
treatment
bacteri
infect
base
evid
correl
decreas
serum
immunoglobulin
level
sever
injuri
patient
howev
human
studi
contradictori
flaw
inadequ
studi
design
one
doubleblind
placebocontrol
studi
show
signific
improv
mortal
infect
high
type
ii
error
low
power
studi
preclud
conclus
real
differ
miss
random
trial
suffici
statist
power
requir
final
patient
cystic
fibrosi
treat
ivig
report
remain
anecdot
perceiv
benefit
shortliv
region
antibodi
antibodi
produc
turn
specif
recogn
antibodi
known
idiotyp
exist
region
suggest
earli
confirm
incorpor
network
theori
antibodyantibodi
interact
thought
occur
normal
human
immun
system
ehrlich
suggest
turn
centuri
autoimmun
red
blood
cell
rbc
could
stop
prevent
antibodi
produc
autoantibodi
antigen
case
rbc
earli
pioneer
suggest
antiantibodi
side
chain
similar
rbc
idea
develop
idiotyp
network
theori
jern
led
idea
intern
imag
antigen
exist
antiantibodi
could
act
surrog
antigen
within
vaccin
past
decad
attempt
made
produc
test
vaccin
protect
variou
infecti
agent
antiidiotyp
antibodi
aia
afford
protect
certain
model
practic
issu
must
consid
product
vaccin
would
expens
may
outweigh
benefit
antibodi
usual
murin
natur
therefor
advers
reaction
problem
genet
engin
might
allow
introduct
human
region
add
cost
therefor
applic
approach
unlik
effect
nativ
antigenbas
vaccin
alreadi
exist
case
hepat
b
howev
aia
vaccin
might
use
exist
vaccin
toxic
eg
pertussi
present
vaccin
ineffect
case
immun
infant
carbohydr
antigen
hemophilu
influenza
group
b
streptococci
proteinbas
prepar
aia
vaccin
may
antigen
individu
exampl
agent
vaccin
aia
test
includ
hepat
b
viru
rabi
viru
reoviru
diphtheria
toxin
poliviru
cours
hiv
clearli
work
need
vaccin
becom
commerci
viabl
select
indic
interferon
first
character
endogen
antivir
agent
clinic
applic
direct
toward
exploit
antineoplast
properti
rather
antivir
potenti
howev
applic
viral
ill
made
three
area
review
illustr
scope
applic
prophylaxi
naturallyacquir
respiratori
infect
treatment
viral
hepat
treatment
hiv
infect
studi
demonstr
prophylact
intranas
administ
interferon
prevent
rhinoviru
coronaviru
infect
experiment
model
human
volunt
two
recent
random
trial
design
implement
test
whether
intranasat
could
reduc
incid
cold
given
household
member
individu
establish
cold
previou
studi
involv
communitybas
field
studi
demonstr
longterm
administr
effect
nasal
intoler
nasal
bleed
stuffi
dryness
develop
week
patient
reduc
effect
result
two
random
trial
shorter
term
therapi
studi
hayden
et
al
healthi
famili
member
famili
randomli
alloc
receiv
interferon
intranas
x
iu
placebo
daili
day
begin
h
onset
cold
symptom
initi
day
incid
respiratori
ill
significantli
reduc
interferon
group
p
similarli
among
cultureproven
rhinoviru
infect
incid
famili
member
receiv
interferon
reduc
p
period
start
begin
treatment
rhinoviru
cold
develop
receiv
interferon
versu
receiv
placebo
p
almost
twice
number
interferon
user
develop
bloodting
mucu
nasal
bleed
vs
p
symptom
much
less
frequent
describ
studi
longer
administr
among
famili
use
interferon
evid
cumul
nasal
toxic
repeat
use
occur
second
larger
studi
similar
design
use
dose
durat
studi
demonstr
reduct
respiratori
ill
overal
reduct
rhinoviru
infect
rate
nasal
bleed
compar
previou
studi
efficaci
shown
involv
infect
symptom
associ
rhinovirus
therefor
time
evid
support
effect
approach
influenza
coronoviru
caus
viral
upper
respiratori
infect
suppress
prevent
rhinoviru
infect
may
costeffect
much
greater
impact
may
achiev
studi
dose
schedul
show
protect
influenza
detail
cost
analysi
studi
rhinoviru
infect
prophylaxi
also
lack
necessari
one
sever
human
viral
infect
interferon
test
earli
hepat
b
infect
time
interferon
avail
rel
crude
prepar
virallystimul
human
blood
buffi
coat
greenberg
et
al
report
first
experi
treat
patient
chronic
activ
hepat
due
hepat
b
infect
interferon
anecdot
report
describ
reproduc
fall
dane
particleassoci
dna
dna
polymeras
activ
well
core
antigen
level
three
patient
high
level
circul
dane
particl
marker
suppress
depend
durat
interferon
administr
longterm
month
administr
also
associ
e
antigen
elimin
surfac
antigen
suppress
effect
chronic
liver
diseas
found
result
encourag
particularli
suggest
infect
may
suppress
abrog
advent
recombin
czif
small
random
trial
report
show
elimin
e
antigen
onethird
patient
treat
month
subsequ
random
trial
carri
test
efficaci
interferon
well
test
ad
efficaci
associ
cours
ofprednison
prior
antivir
therapi
onehundredandsixtynin
patient
randomli
assign
one
four
treatment
prednison
mg
daili
taper
week
follow
interferon
x
unit
daili
week
placebo
follow
interferon
placebo
follow
interferon
x
unit
daili
week
observ
alon
primari
object
test
efficaci
interferon
secondari
object
efficaci
ad
prednison
estim
sampl
size
given
accept
level
type
type
ii
error
howev
despit
small
number
patient
per
group
disappear
marker
infect
ie
e
antigen
viral
dna
significantli
frequent
higher
dose
interferon
arm
without
prednison
furthermor
sign
hepat
periport
necrosi
improv
p
liver
function
test
normal
respond
patient
short
onethird
patient
histolog
biochem
evid
remiss
viral
hepat
b
dose
schedul
interferon
lower
dose
effect
patient
lower
level
hepat
b
viral
dna
serum
greater
likelihood
respons
longer
followup
need
determin
longterm
remiss
achiev
patient
studi
follow
year
whether
incid
hepatocellular
carcinoma
reduc
also
better
therapi
need
high
circul
level
viral
dna
two
recent
random
trial
test
interferon
alpha
chronic
hepat
c
smaller
trial
biscegli
et
al
random
patient
chronic
hepat
c
receiv
x
unit
subcutan
three
time
per
week
month
placebo
sampl
serum
tissu
analyz
result
compar
use
twosampl
ttest
twosampl
wilcoxon
test
signific
improv
liver
function
histolog
test
seen
interferontr
compar
placebotr
patient
serolog
complet
remiss
occur
interferontr
patient
month
therapi
two
ten
patient
still
normal
liver
function
valu
therefor
benefit
temporari
shortliv
larger
trial
random
patient
one
two
dose
interferon
alpha
x
unit
versu
x
unit
three
time
weekli
week
treatment
thu
nearli
three
time
mani
patient
treat
per
arm
primari
outcom
includ
serolog
histolog
evid
remiss
relaps
rate
treatment
period
signific
proport
patient
receiv
high
p
low
p
dose
interferon
enter
serolog
complet
near
complet
remiss
compar
control
patient
higher
proport
highdos
patient
complet
remiss
compar
lowdos
patient
vs
howev
relaps
occur
within
month
complet
therapi
patient
receiv
high
lowdos
interferon
respect
hepat
b
result
encourag
yet
definit
improv
surviv
qualiti
life
must
pursu
futur
trial
treatment
hiv
infect
csf
antiidiotyp
antibodi
aia
ivig
alreadi
discuss
howev
strategi
also
test
devast
diseas
lane
et
al
randomli
alloc
patient
asymptomat
hiv
infect
count
cellsmm
posit
peripher
blood
cultur
hiv
antigenemia
receiv
odf
x
unit
daili
week
placebo
despit
small
sampl
size
patient
receiv
interferon
hiv
posit
becam
hiv
neg
compar
two
patient
receiv
placebo
p
howev
interferontr
patient
stop
treatment
due
toxic
leav
averag
daili
dose
x
unit
studi
group
granulocytopenia
elev
liver
enzym
note
addit
usual
flulik
symptom
despit
followup
period
rang
month
patient
receiv
interferon
develop
aidsrel
opportunist
infect
compar
placebotr
patient
p
result
show
interferon
activ
hiv
infect
dose
well
toler
patient
similar
problem
evid
treatment
aidsrel
kaposi
sarcoma
interferon
carter
et
al
demonstr
clinic
immunolog
improv
aid
patient
use
ampligen
doublestrand
rna
interferon
induc
much
work
need
done
find
effect
dose
schedul
either
alon
like
combin
agent
one
nonrandom
trial
ofzidovudin
interferon
suggest
greater
toler
lower
dose
interferon
depend
dose
zidovudin
evid
antivir
activ
one
vaccin
strategi
hiv
infect
use
aia
alreadi
mention
strategi
focu
deliveri
recognit
natur
synthet
hivspecif
antigen
earli
studi
found
poor
recognit
antigen
immun
system
deliv
alon
attempt
favour
modifi
immun
respons
includ
use
wholekil
viru
antigenvaccinia
construct
latter
involv
combin
ofvaccinia
viru
hiv
antigen
vaccin
order
improv
recognit
immun
respons
hiv
antigen
exampl
biolog
modif
also
use
strategi
tumour
vaccin
develop
primat
studi
suggest
vaccin
may
protect
hiv
infect
much
work
necessari
compar
human
trial
design
implement
serum
high
antihiv
titr
monoclon
antibodi
test
passiv
serotherapi
uncontrol
trial
former
document
remiss
antigenemia
symptomat
improv
loss
cultur
hiv
blood
clinic
trial
hiv
monoclon
antibodi
moab
done
moab
greater
affin
direct
conserv
epitop
develop
order
overcom
genet
fluctuat
hiv
strain
molecul
may
use
passiv
therapi
due
abil
bend
neutral
hiv
includ
genet
engin
protein
conjug
constant
region
enterotoxin
former
could
also
use
bind
hivinfect
cell
would
bind
hiv
surfac
antigen
cell
kill
could
mediat
complement
antibodymedi
cytotox
besid
interferon
immunomodul
drug
test
includ
thymic
hormon
demonstr
immunorestor
clinic
benefit
thu
far
chemic
immunomodul
latter
includ
nucleic
acid
analog
isoprinosin
thiol
diethyldithiocarbom
dtc
imidazol
cyanoaziridin
azimexon
isoprinosin
demonstr
improv
cellmedi
immun
symptomat
improv
fewer
infect
hiv
patient
dtc
test
random
trial
amelior
symptom
reduct
infect
improv
surviv
demonstr
among
benefit
appear
particularli
promis
patient
advanc
stage
aid
final
azimexon
undergon
preliminari
human
trial
associ
restor
symptom
relief
use
tradit
chines
treatment
brm
recent
review
experiment
evid
prepar
reduc
symptom
sepsi
induc
lp
administr
oral
administr
three
tradit
prepar
week
prior
ip
instil
p
aeruginosa
mice
result
improv
surviv
though
statist
test
data
report
vitro
studi
macrophag
shosaikoto
tradit
prepar
prime
mice
show
enhanc
chemiluminesc
greater
number
splenic
macrophag
compar
control
studi
demonstr
increas
immun
respons
includ
antibodi
respons
increas
phagocytosi
stimul
macrophag
activ
compon
seem
found
crude
herbal
compon
bupleuri
radix
angelica
radix
former
contain
pharmacolog
activ
glycosid
antiinflammatori
immunemodul
properti
similar
corticosteroid
prepar
activ
investig
test
japan
therapeut
potenti
cancer
infecti
diseas
